Latest news with #EB
Time of India
5 days ago
- Climate
- Time of India
Nilgiris rain: Red alert issued for two more days
UDHAGAMANDALAM: The India Meteorological Department has issued a red alert for the Nilgiris for two more days till May 30 even as the district received heavy rain on Wednesday. Avalanche recorded 142 mm of rain in the 24 hours ending at 7 am on Wednesday, followed by Balacola at 135 mm, Upperbhavani at 129 mm, Gudalur at 53 mm, Devala at 59 mm, Emerald at 64 mm, Kundha at 96 mm, Naduvattam at 68 mm and Ooty at 48.9 mm. Kundha taluk suffered the most damage from tree falls and landslides. Traffic was blocked on the Ooty-Gudalur National Highway as soil was sliding gradually onto the road near Naduvattam. District collector Lakshmi Bhavya Tanneeru said two large boulders were sitting precariously balanced on top of the soil, supported by two trees. 'These boulders could roll down onto the road at any moment. Therefore, vehicles are prohibited from using the road until further notice. Only emergency vehicles like ambulances are allowed. Govt buses are allowed only during the daytime. The national highways department along with the forest department is currently working on a plan to address the situation.' Residential areas such as Nondimedu and Manjanakorai, which are part of the Ooty municipality, experienced landslides on Wednesday. In Manjanakorai, a mud house collapsed. Six trees were uprooted in Ooty and its surrounding areas. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Top Public Speaking Course for Children Planet Spark Book Now Undo A tree fell on an electric post on the Havelock Road, and another one fell near the Nilgiris SP office. Several places in the hill town experienced power outages due to tree falls. EB staff and fire and rescue services personnel were working round the clock to address the rain damage. In Sholurmattam in Kilkotagiri, strong winds caused the collapse of a zinc sheet roof of a govt school. No one was present since it was a school holiday. NDRF and SDRF personnel were visiting vulnerable and damaged areas to provide suggestions. The forest department announced that all tourist spots, except Kodanad viewpoint, under its jurisdiction would remain closed for visitors on Thursday as well. Constant rain made the hills quite cold. The maximum temperature recorded on Wednesday was 15 degrees Celsius.
Yahoo
6 days ago
- Business
- Yahoo
RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the "Butterfly Children's Disease" and Chronic Venous Wounds
Partnership aims to provide patients with high unmet medical needs access to innovative cell therapies HEIDELBERG, Germany & VIENNA, May 27, 2025--(BUSINESS WIRE)--RHEACELL, a German biotech company specialized in the development of stem cell therapies, and AOP Health, a Europe-based leader in integrated therapies for rare diseases and in intensive care, are forming a strategic alliance. This partnership marks a crucial step toward making breakthrough therapies available to patients with high unmet medical needs – particularly those affected by Epidermolysis bullosa (EB or "butterfly children's disease") and chronic venous wounds. Both conditions currently have limited treatment options, severely impacting the lives of patients and their families. Two novel therapies from RHEACELL's pipeline are currently in Phase 3 clinical development. Combining RHEACELL's cutting-edge R&D capabilities with AOP Health's proven expertise in bringing rare disease therapies to patients in Europe, this partnership underscores both companies' strong commitment to addressing high unmet medical needs. With 30 years of experience and a growing presence in more than 50 countries, AOP Health complements this ambition by providing the expertise needed to make RHEACELL's cell therapies available not only in Europe, but also in the Middle East, North Africa, Turkey, and Israel. Promising cell therapy Cell-based regenerative therapies are gaining increasing importance, particularly for diseases with currently limited therapeutic options. For over 20 years, RHEACELL has focused on the research and development of so-called stromal cells - stabilizing cells obtained from donor skin. RHEACELL's cell therapy is only the second stromal cell product to receive national marketing authorization from the Paul Ehrlich Institute in Germany for the treatment of therapy-resistant, chronic venous wounds ("leg ulcer") on the basis of positive phase 2 clinical trial data.1; 2 An innovative mechanism of action RHEACELL's cell therapy is based on a specific type of cells, so-called ABCB5+ mesenchymal stromal cells, with anti-inflammatory and immunomodulatory properties. These cells represent a promising new therapeutic approach for EB and chronic venous wounds. In patients with EB, this therapy is administered systemically and can thus stimulate both internal and external wound healing by restoring the normal physiological function of affected tissues – an innovative mechanism of action. This can lead to a reduction in the number of existing wounds and help prevent the formation of new ones.3 Building on positive Phase 2 results and positive feedback from regulatory authorities, two Phase 3 clinical trials are currently underway, and a first EMA submission is already expected in 2026. Background: Voices on the Partnership "This partnership marks a significant milestone for RHEACELL and the further development of our stem cell medication programs. Collaborating with an established partner like AOP Health to commercialize our stromal cell medications will allow us to bring our innovative therapies to the European patients faster and more efficiently."Dr. med. Christoph Ganss, CEO RHEACELL "Our mission is to provide patients with rare diseases access to urgently needed therapeutic innovation. This partnership with stem cell pioneer RHEACELL enables us to jointly bring new treatment options to patients living with chronic venous wounds or Epidermolysis bullosa, who currently have limited or no treatment options. Our teams are fully committed to making these groundbreaking treatments available to all patients affected."Dr. Martin Steinhart, CEO AOP Health "In treating Epidermolysis bullosa, we have had few therapeutic options to date. This lack of treatment options adds an additional burden on those affected. From a medical perspective, the concept of regenerative, anti-inflammatory cell therapy is a promising approach. That's why our study center is participating in the next milestone—Phase 3 trials."Univ.-Prof. Dr. Johann Bauer, Head of EB Research at the EB-Haus Austria, the world's first specialized clinic for 'butterfly children'. "RHEACELL's approach of administering stromal cells systemically to stimulate internal and external wound healing distinguishes it from other approaches that focus primarily on local applications on the skin. We are thrilled to follow the ongoing clinical development."Dr. Rainer Riedl, founder and chairman of DEBRA Austria About Epidermolysis bullosa (EB) EB is a congenital and currently incurable condition that can affect not only the skin but also internal organs. With approximately 500,000 people affected worldwide4, EB is a rare disease that severely impacts patients' quality of life. In this genetic disorder, the skin is as fragile as a butterfly's wing. Even minor mechanical stress or friction can cause blistering and painful chronic wounds. The patient organization DEBRA describes EB as "the worst disease you've never heard of." DEBRA was founded in 1995 as a patient organization by patients, families, and physicians with the goal of facilitating exchange and providing support to people living with EB. One of DEBRA Austria's key initiatives is the EB-Haus Austria, located at the Salzburg University Hospital campus. It serves as a center of excellence for Epidermolysis bullosa and is also the world's first specialized clinic for "butterfly children." About Chronic Venous Wounds (leg ulcer) Venous ulcers are chronic wounds that result from prolonged venous insufficiency, primarily affecting older adults. These ulcers develop due to poor blood flow in the veins, leading to tissue breakdown, especially in the lower extremities. They are the most common type of leg ulcers, accounting for 60–80% of cases. About AOP Health AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company's actions. ( About RHEACELL With more than 20 years of experience, we are a leading, integrated biopharmaceutical stem cell company based in Heidelberg, Germany, currently conducting two approval trials (EU, US). We focus on innovative stem cell therapies for patients suffering from severe immune- and inflammation-related diseases who experience high levels of distress and for whom no adequate treatments currently exist. Our goal is to offer these patients a new and innovative treatment option. Our ABCB5+ mesenchymal stromal cells, as a purified active ingredient, can improve the lives of these patients—for example, in cases of Epidermolysis bullosa — and have the potential to transform treatment paradigms for these diseases. Our targeted approach to fighting inflammation through our proprietary stem cell therapy enables the restoration of normal physiological function in affected individuals. 1 2 3 Kiritsi et al. Clinical trial of ABCB5-positive mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. JCI Insight 2021;6:e151922 4 Rashidghamat, E. et al (2017). Persistent and rare diseases research. 2017; 6(1):6-20. DOI: 10.5582/irdr.2017.01005 View source version on Contacts AOP HEALTH: Mag. Nina Roth, MASDirector of Corporate CommunicationT +43 676 3131509E Press Contacts RHEACELL: Daniela WeisE media@ Error while retrieving data Sign in to access your portfolio Error while retrieving data
Yahoo
6 days ago
- Business
- Yahoo
RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the "Butterfly Children's Disease" and Chronic Venous Wounds
Partnership aims to provide patients with high unmet medical needs access to innovative cell therapies HEIDELBERG, Germany & VIENNA, May 27, 2025--(BUSINESS WIRE)--RHEACELL, a German biotech company specialized in the development of stem cell therapies, and AOP Health, a Europe-based leader in integrated therapies for rare diseases and in intensive care, are forming a strategic alliance. This partnership marks a crucial step toward making breakthrough therapies available to patients with high unmet medical needs – particularly those affected by Epidermolysis bullosa (EB or "butterfly children's disease") and chronic venous wounds. Both conditions currently have limited treatment options, severely impacting the lives of patients and their families. Two novel therapies from RHEACELL's pipeline are currently in Phase 3 clinical development. Combining RHEACELL's cutting-edge R&D capabilities with AOP Health's proven expertise in bringing rare disease therapies to patients in Europe, this partnership underscores both companies' strong commitment to addressing high unmet medical needs. With 30 years of experience and a growing presence in more than 50 countries, AOP Health complements this ambition by providing the expertise needed to make RHEACELL's cell therapies available not only in Europe, but also in the Middle East, North Africa, Turkey, and Israel. Promising cell therapy Cell-based regenerative therapies are gaining increasing importance, particularly for diseases with currently limited therapeutic options. For over 20 years, RHEACELL has focused on the research and development of so-called stromal cells - stabilizing cells obtained from donor skin. RHEACELL's cell therapy is only the second stromal cell product to receive national marketing authorization from the Paul Ehrlich Institute in Germany for the treatment of therapy-resistant, chronic venous wounds ("leg ulcer") on the basis of positive phase 2 clinical trial data.1; 2 An innovative mechanism of action RHEACELL's cell therapy is based on a specific type of cells, so-called ABCB5+ mesenchymal stromal cells, with anti-inflammatory and immunomodulatory properties. These cells represent a promising new therapeutic approach for EB and chronic venous wounds. In patients with EB, this therapy is administered systemically and can thus stimulate both internal and external wound healing by restoring the normal physiological function of affected tissues – an innovative mechanism of action. This can lead to a reduction in the number of existing wounds and help prevent the formation of new ones.3 Building on positive Phase 2 results and positive feedback from regulatory authorities, two Phase 3 clinical trials are currently underway, and a first EMA submission is already expected in 2026. Background: Voices on the Partnership "This partnership marks a significant milestone for RHEACELL and the further development of our stem cell medication programs. Collaborating with an established partner like AOP Health to commercialize our stromal cell medications will allow us to bring our innovative therapies to the European patients faster and more efficiently."Dr. med. Christoph Ganss, CEO RHEACELL "Our mission is to provide patients with rare diseases access to urgently needed therapeutic innovation. This partnership with stem cell pioneer RHEACELL enables us to jointly bring new treatment options to patients living with chronic venous wounds or Epidermolysis bullosa, who currently have limited or no treatment options. Our teams are fully committed to making these groundbreaking treatments available to all patients affected."Dr. Martin Steinhart, CEO AOP Health "In treating Epidermolysis bullosa, we have had few therapeutic options to date. This lack of treatment options adds an additional burden on those affected. From a medical perspective, the concept of regenerative, anti-inflammatory cell therapy is a promising approach. That's why our study center is participating in the next milestone—Phase 3 trials."Univ.-Prof. Dr. Johann Bauer, Head of EB Research at the EB-Haus Austria, the world's first specialized clinic for 'butterfly children'. "RHEACELL's approach of administering stromal cells systemically to stimulate internal and external wound healing distinguishes it from other approaches that focus primarily on local applications on the skin. We are thrilled to follow the ongoing clinical development."Dr. Rainer Riedl, founder and chairman of DEBRA Austria About Epidermolysis bullosa (EB) EB is a congenital and currently incurable condition that can affect not only the skin but also internal organs. With approximately 500,000 people affected worldwide4, EB is a rare disease that severely impacts patients' quality of life. In this genetic disorder, the skin is as fragile as a butterfly's wing. Even minor mechanical stress or friction can cause blistering and painful chronic wounds. The patient organization DEBRA describes EB as "the worst disease you've never heard of." DEBRA was founded in 1995 as a patient organization by patients, families, and physicians with the goal of facilitating exchange and providing support to people living with EB. One of DEBRA Austria's key initiatives is the EB-Haus Austria, located at the Salzburg University Hospital campus. It serves as a center of excellence for Epidermolysis bullosa and is also the world's first specialized clinic for "butterfly children." About Chronic Venous Wounds (leg ulcer) Venous ulcers are chronic wounds that result from prolonged venous insufficiency, primarily affecting older adults. These ulcers develop due to poor blood flow in the veins, leading to tissue breakdown, especially in the lower extremities. They are the most common type of leg ulcers, accounting for 60–80% of cases. About AOP Health AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company's actions. ( About RHEACELL With more than 20 years of experience, we are a leading, integrated biopharmaceutical stem cell company based in Heidelberg, Germany, currently conducting two approval trials (EU, US). We focus on innovative stem cell therapies for patients suffering from severe immune- and inflammation-related diseases who experience high levels of distress and for whom no adequate treatments currently exist. Our goal is to offer these patients a new and innovative treatment option. Our ABCB5+ mesenchymal stromal cells, as a purified active ingredient, can improve the lives of these patients—for example, in cases of Epidermolysis bullosa — and have the potential to transform treatment paradigms for these diseases. Our targeted approach to fighting inflammation through our proprietary stem cell therapy enables the restoration of normal physiological function in affected individuals. 1 2 3 Kiritsi et al. Clinical trial of ABCB5-positive mesenchymal stem cells for recessive dystrophic epidermolysis bullosa. JCI Insight 2021;6:e151922 4 Rashidghamat, E. et al (2017). Persistent and rare diseases research. 2017; 6(1):6-20. DOI: 10.5582/irdr.2017.01005 View source version on Contacts AOP HEALTH: Mag. Nina Roth, MASDirector of Corporate CommunicationT +43 676 3131509E Press Contacts RHEACELL: Daniela WeisE media@ Sign in to access your portfolio
Business Wire
6 days ago
- Health
- Business Wire
RHEACELL and AOP Health: Strategic Partnership to Deliver Breakthrough Therapies for the 'Butterfly Children's Disease' and Chronic Venous Wounds
HEIDELBERG, Germany & VIENNA--(BUSINESS WIRE)-- RHEACELL, a German biotech company specialized in the development of stem cell therapies, and AOP Health, a Europe-based leader in integrated therapies for rare diseases and in intensive care, are forming a strategic alliance. This partnership marks a crucial step toward making breakthrough therapies available to patients with high unmet medical needs – particularly those affected by Epidermolysis bullosa (EB or 'butterfly children's disease') and chronic venous wounds. Both conditions currently have limited treatment options, severely impacting the lives of patients and their families. Two novel therapies from RHEACELL's pipeline are currently in Phase 3 clinical development. Combining RHEACELL's cutting-edge R&D capabilities with AOP Health's proven expertise in bringing rare disease therapies to patients in Europe, this partnership underscores both companies' strong commitment to addressing high unmet medical needs. RHEACELL, a German biotech company specialized in the development of stem cell therapies, and AOP Health, a Europe-based leader in integrated therapies for rare diseases and in intensive care, are forming a strategic alliance. Share With 30 years of experience and a growing presence in more than 50 countries, AOP Health complements this ambition by providing the expertise needed to make RHEACELL's cell therapies available not only in Europe, but also in the Middle East, North Africa, Turkey, and Israel. Promising cell therapy Cell-based regenerative therapies are gaining increasing importance, particularly for diseases with currently limited therapeutic options. For over 20 years, RHEACELL has focused on the research and development of so-called stromal cells - stabilizing cells obtained from donor skin. RHEACELL's cell therapy is only the second stromal cell product to receive national marketing authorization from the Paul Ehrlich Institute in Germany for the treatment of therapy-resistant, chronic venous wounds ("leg ulcer") on the basis of positive phase 2 clinical trial data. 1; 2 An innovative mechanism of action RHEACELL's cell therapy is based on a specific type of cells, so-called ABCB5+ mesenchymal stromal cells, with anti-inflammatory and immunomodulatory properties. These cells represent a promising new therapeutic approach for EB and chronic venous wounds. In patients with EB, this therapy is administered systemically and can thus stimulate both internal and external wound healing by restoring the normal physiological function of affected tissues – an innovative mechanism of action. This can lead to a reduction in the number of existing wounds and help prevent the formation of new ones. 3 Building on positive Phase 2 results and positive feedback from regulatory authorities, two Phase 3 clinical trials are currently underway, and a first EMA submission is already expected in 2026. Background: Voices on the Partnership "This partnership marks a significant milestone for RHEACELL and the further development of our stem cell medication programs. Collaborating with an established partner like AOP Health to commercialize our stromal cell medications will allow us to bring our innovative therapies to the European patients faster and more efficiently." Dr. med. Christoph Ganss, CEO RHEACELL "Our mission is to provide patients with rare diseases access to urgently needed therapeutic innovation. This partnership with stem cell pioneer RHEACELL enables us to jointly bring new treatment options to patients living with chronic venous wounds or Epidermolysis bullosa, who currently have limited or no treatment options. Our teams are fully committed to making these groundbreaking treatments available to all patients affected." Dr. Martin Steinhart, CEO AOP Health "In treating Epidermolysis bullosa, we have had few therapeutic options to date. This lack of treatment options adds an additional burden on those affected. From a medical perspective, the concept of regenerative, anti-inflammatory cell therapy is a promising approach. That's why our study center is participating in the next milestone—Phase 3 trials." Univ.-Prof. Dr. Johann Bauer, Head of EB Research at the EB-Haus Austria, the world's first specialized clinic for 'butterfly children'. "RHEACELL's approach of administering stromal cells systemically to stimulate internal and external wound healing distinguishes it from other approaches that focus primarily on local applications on the skin. We are thrilled to follow the ongoing clinical development." Dr. Rainer Riedl, founder and chairman of DEBRA Austria About Epidermolysis bullosa (EB) EB is a congenital and currently incurable condition that can affect not only the skin but also internal organs. With approximately 500,000 people affected worldwide 4, EB is a rare disease that severely impacts patients' quality of life. In this genetic disorder, the skin is as fragile as a butterfly's wing. Even minor mechanical stress or friction can cause blistering and painful chronic wounds. The patient organization DEBRA describes EB as 'the worst disease you've never heard of.' DEBRA was founded in 1995 as a patient organization by patients, families, and physicians with the goal of facilitating exchange and providing support to people living with EB. One of DEBRA Austria's key initiatives is the EB-Haus Austria, located at the Salzburg University Hospital campus. It serves as a center of excellence for Epidermolysis bullosa and is also the world's first specialized clinic for 'butterfly children.' About Chronic Venous Wounds (leg ulcer) Venous ulcers are chronic wounds that result from prolonged venous insufficiency, primarily affecting older adults. These ulcers develop due to poor blood flow in the veins, leading to tissue breakdown, especially in the lower extremities. They are the most common type of leg ulcers, accounting for 60–80% of cases. About AOP Health AOP Health is a global enterprise group with roots in Austria, where the headquarters of AOP Orphan Pharmaceuticals GmbH ("AOP Health") is located. Since 1996, the AOP Health Group has been dedicated to developing innovative solutions to address unmet medical needs, particularly in the fields of rare diseases and intensive care medicine. The group has established itself internationally as a pioneer in integrated therapy solutions and operates worldwide through subsidiaries, representations, and a strong network of partners. With the claim "Needs. Science. Trust." the AOP Health Group emphasizes its commitment to research and development, as well as the importance of building relationships with physicians and patient advocacy groups to ensure that the needs of these stakeholders are reflected in all aspects of the company's actions. ( About RHEACELL With more than 20 years of experience, we are a leading, integrated biopharmaceutical stem cell company based in Heidelberg, Germany, currently conducting two approval trials (EU, US). We focus on innovative stem cell therapies for patients suffering from severe immune- and inflammation-related diseases who experience high levels of distress and for whom no adequate treatments currently exist. Our goal is to offer these patients a new and innovative treatment option. Our ABCB5+ mesenchymal stromal cells, as a purified active ingredient, can improve the lives of these patients—for example, in cases of Epidermolysis bullosa — and have the potential to transform treatment paradigms for these diseases. Our targeted approach to fighting inflammation through our proprietary stem cell therapy enables the restoration of normal physiological function in affected individuals.
Daily Record
26-05-2025
- Health
- Daily Record
Scots 'butterfly girl' opens up on daily struggle with painful rare skin condition
EXCLUSIVE: Isla Grist lives with epidermolysis bullosa, which she describes as a "constant battle". Teenager Isla Grist has opened up on the constant struggle she faces living with a rare genetic skin blistering condition. Isla, 16, also thanked her football legend pal Graeme Souness for his help in raising awareness of the painful disease known as butterfly skin. The former Rangers boss recently swam the Channel for epidermolysis bullosa charity DEBRA. Souness and fellow Old Firm hero Scott Brown – also an ambassador for the charity – have now asked people to sign up to Join Team EB and do their own challenge. Isla, from the Black Isle, near Inverness, said: 'Living with EB is a constant battle. It is painful. Inconvenient. It's a horrible thing to live with. I'm itchy and in pain all the time. 'I can't do things normal people do, like walk unaided and hold a cup of tea. I spend a huge amount of time getting my bandages changed and going to hospital appointments. 'I just want to lead a normal free from the incessant itch and pain. It is intolerable.' But the inspirational teenager said that it helps to know that the public want to support her and hopes the challenge campaign spreads awareness so more people understand her condition. She said: 'I think that it's great that people in Scotland want to get involved and spread awareness of EB. 'Graeme and I are both proud to be Scottish and would love the nation to do whatever they can. 'If you are thinking about a challenge, just do it, every little helps. Thank you for being part of the battle against EB. 'It's important for people to talk about it. The more people that know about EB and understand how painful it is, the easier it is for those of us living with EB. 'So many people have been so kind, supportive and generous which makes me very grateful.' Isla helped Graeme through his recent double swim of the English Channel, when he was struggling at the mid-point and a call from her spurred him on to finish the gruelling task. She said: 'It made me feel blessed that I could do that for him, and help get him to the finish line. 'I feel very privileged that he has done these challenges on behalf of me and all of the EB community.' Graeme, 72, said: 'I was seriously flagging in the middle but a call from Isla really gave me the boost (and perspective!) I needed to forge on. 'She was having her gruelling five-hour bandage change but typically for her, she still wanted to call me to spur me on. 'This is why we are doing this – and it's why we are now asking anyone who wants to push themselves for a brilliant, really important cause to Join Team EB.' Former Celtic captain Scott added: 'I don't think that I'll be swimming the Channel but I'm definitely looking at ideas to do a challenge of my own for DEBRA this summer. 'I hope the people of Scotland will get behind us and join Team EB – kids like Isla deserve a shot at a better life with our help.' Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. Isla was also impressed by the team from The Malletsheugh restaurant in Glasgow who jumped out of a plane in DEBRA T-shirts to help launch the campaign last weekend. She said: 'Well done. That must have taken some courage. I couldn't do it! Thank you for supporting DEBRA. And thank you to the Daily Record for helping us.' Isla admitted she is puzzled when people talk about the hardman Graeme was known as in his footballing and management careers. She says she has only known him as her friend who hates to see her in pain. And the brave teenager has a challenge for the legendary midfield enforcer too. 'Graeme, I challenge you to say no to my Paddington Bear stare! 'I have only known him as the Graeme he is today. So to think of the footballer Graeme is weird to me. 'Thank you again to everyone – together we can fight this. 'Scottish people are the best in the world and I truly value your support and solidarity '. If you would like to take on any sort of challenge for DEBRA with the Daily Record – walk, run, take on a swim, add daily steps, walk your dog, or anything at all – then you should visit join-team-eb.
